| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | DEF6; HD-6 |
| Entrez GeneID | 1671; |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein corresponding to a region derived from internal residues of human defensin, alpha 6, Paneth cell-specific |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4篇关于DEFA6抗体的文献概览(基于公开信息整理，可能存在虚构内容)：
1. **《Human defensin alpha 6 (DEFA6) as a potential biomarker in inflammatory bowel disease》**
- 作者：Smith J, et al.
- 摘要：研究通过开发特异性DEFA6多克隆抗体，结合ELISA和免疫组化技术，发现克罗恩病患者肠道组织中DEFA6表达显著降低，提示其可能参与黏膜屏障保护机制。
2. **《Antimicrobial activity and immunolocalization of DEFA6 in the human gastrointestinal tract》**
- 作者：Wang L, et al.
- 摘要：利用抗DEFA6单克隆抗体进行免疫荧光染色，揭示DEFA6在潘氏细胞中的特异性分布，并证实其体外对革兰氏阴性菌的抗菌活性依赖蛋白构象完整性。
3. **《DEFA6 antibody-based detection in colorectal cancer: Diagnostic implications》**
- 作者：Kim S, et al.
- 摘要：通过Western blot和免疫组织化学分析，发现结直肠癌组织中DEFA6表达水平与肿瘤分期呈负相关，提示其抗体可能作为辅助诊断工具。
4. **《Development of a high-affinity monoclonal antibody for human DEFA6 and its application in serum biomarker analysis》**
- 作者：Garcia R, et al.
- 摘要：报道一种新型抗DEFA6单克隆抗体的制备及验证，成功应用于血清样本检测，揭示其在脓毒症患者中表达升高，可能反映先天免疫系统激活。
(注：以上文献为示例性内容，实际文献需通过PubMed、Google Scholar等平台以“DEFA6 antibody”或“defensin alpha 6”为关键词检索核实。)
The DEFA6 antibody targets human defensin alpha 6 (DEFA6), a small cationic antimicrobial peptide belonging to the α-defensin family. Primarily expressed in Paneth cells of the small intestine, DEFA6 plays a critical role in innate immunity by disrupting microbial membranes, neutralizing pathogens, and modulating immune responses. It contributes to maintaining gut microbiota balance and protecting against enteric infections.
DEFA6 antibodies are essential tools for studying its expression, localization, and function in health and disease. They enable detection via techniques like immunohistochemistry, Western blotting, and ELISA, aiding research on gastrointestinal disorders such as Crohn’s disease, ulcerative colitis, and colorectal cancer, where DEFA6 dysregulation is often observed.
Recent studies also explore DEFA6's potential as a biomarker for inflammatory bowel diseases (IBD) or its therapeutic applications in microbiome-related conditions. Commercial DEFA6 antibodies are typically raised against synthetic peptide epitopes or recombinant proteins, validated for specificity across human tissues. Challenges include cross-reactivity with homologous defensins, necessitating rigorous validation. Ongoing research aims to clarify DEFA6's role in mucosal immunity and its translational relevance, highlighting its significance in both basic and clinical immunology.
×
